NeuBase Therapeutics (NASDAQ:NBSE) Sees Large Volume Increase

NeuBase Therapeutics (NASDAQ:NBSE) saw unusually-high trading volume on Wednesday . Approximately 947,500 shares traded hands during trading, an increase of 532% from the previous session’s volume of 149,882 shares.The stock last traded at $6.32 and had previously closed at $5.05.

Several analysts have recently commented on the stock. Oppenheimer assumed coverage on shares of NeuBase Therapeutics in a research note on Wednesday. They issued an “outperform” rating and a $14.00 target price for the company. ValuEngine lowered shares of NeuBase Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 16th. HC Wainwright began coverage on shares of NeuBase Therapeutics in a report on Tuesday, October 29th. They set a “buy” rating and a $14.00 price target for the company. Finally, BTIG Research began coverage on shares of NeuBase Therapeutics in a research report on Tuesday, September 24th. They issued a “buy” rating and a $15.00 price objective for the company.

The firm has a 50 day moving average of $4.95.

A hedge fund recently bought a new stake in NeuBase Therapeutics stock. Heritage Wealth Advisors acquired a new position in shares of NeuBase Therapeutics (NASDAQ:NBSE) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 11,000 shares of the company’s stock, valued at approximately $54,000. Heritage Wealth Advisors owned 0.06% of NeuBase Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.81% of the company’s stock.

NeuBase Therapeutics Company Profile (NASDAQ:NBSE)

NeuBase Therapeutics, Inc, a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders.

Read More: How Investors Can Profit from Options Trading

Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.